ticoagulation as INR levels can be labile in many patients on VKAs.
According to the current national and international guidelines, although therapy with novel oral anticoagulants (NOACs) is suggested over VKAs, due to reimbursement problems, many people with deep vein thrombosis of the leg or pulmonary embolism are still receiving VKA therapy.2 , 3 VKAs are also used after venous stenting procedures in patient